Friday, July 10, 2026

pharma · Head and Neck Neoplasms · Rheumatoid Arthritis

Chinese University of

Chinese University of clinical programs — 16 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

CN HQ
NMPA registrant Type
Company details
Status
Public
HQ
CN
Programs
42
Drugs
55
Patents
0
Intelligence · Clinical Programs

Chinese University of projects

16 ClinicalTrials.gov programs sponsored by Chinese University of.

Chinese University of has 16 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Almonertinib 110 MG

    Chinese University of Hong Kong

    Rare Tumor

    phase 2 small molecule active

    1 trial
  2. Apatinib

    Chinese University of Hong Kong

    Head and Neck Neoplasms

    phase 2 small molecule active

    1 trial
  3. Apatinib Mesylate +SHR-1210

    Chinese University of Hong Kong

    Hepatocellular Carcinoma

    phase 2 other active

    1 trial
  4. Chinese Herb

    Chinese University of Hong Kong

    COVID-19

    phase 2 small molecule active

    1 trial
  5. Chinese Medicine Oral Rinse Formula-I (CMORF-I)

    Chinese University of Hong Kong

    Head and Neck Neoplasms

    phase 2 small molecule active

    1 trial
  6. Cisplatin and Doxorubicin

    Chinese University of Hong Kong

    Gastric Cancer Peritoneal Metastases

    phase 2 small molecule active

    1 trial
  7. Fezolinetant

    Chinese University of Hong Kong

    Vasomotor Symptoms

    phase 2 small molecule active

    1 trial
  8. Fludrocortisone 100 mcg daily

    Chinese University of Hong Kong

    Sepsis

    phase 2 small molecule active

    1 trial
  9. Iparomlimab/Tuvonralimab

    Chinese University of Hong Kong

    LOCALLY ADVANCED CERVICAL CANCERS

    phase 2 small molecule active

    1 trial
  10. Jinling37ICUZCY

    Chinese University of Hong Kong

    Acute Lower Gastrointestinal Dysfunction

    phase 2 other active

    1 trial
  11. Nimotuzumab

    Chinese University of Hong Kong

    Esophageal Cancer

    phase 2 small molecule completed

    1 trial
  12. Per-Oral Endoscopic Myotomy

    Chinese University of Hong Kong

    Primary Esophageal Motility Disorders Including Achalasia and Hypertensive LES

    phase 2 other active

    1 trial
  13. Programmed Cell Death Protein 1 Inhibitor

    Chinese University of Hong Kong

    Locally Advanced Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial
  14. RC48-ADC

    Chinese University of Hong Kong

    Muscle Invasive Bladder Carcinoma

    phase 2 small molecule active

    1 trial
  15. SIRT Yttrium-90

    Chinese University of Hong Kong

    Cholangio Carcinoma

    phase 2 small molecule completed

    1 trial
  16. rituximab

    Chinese University of Hong Kong

    Systemic Lupus Erythematosus

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Chinese University of have?

16 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.